Molecular Mechanisms and Emerging Therapeutics for Osteoporosis
Top Cited Papers
Open Access
- 14 October 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (20), 7623
- https://doi.org/10.3390/ijms21207623
Abstract
Osteoporosis is the most common chronic metabolic bone disease. It has been estimated that more than 10 million people in the United States and 200 million men and women worldwide have osteoporosis. Given that the aging population is rapidly increasing in many countries, osteoporosis could become a global challenge with an impact on the quality of life of the affected individuals. Osteoporosis can be defined as a condition characterized by low bone density and increased risk of fractures due to the deterioration of the bone architecture. Thus, the major goal of treatment is to reduce the risk for fractures. There are several treatment options, mostly medications that can control disease progression in risk groups, such as postmenopausal women and elderly men. Recent studies on the basic molecular mechanisms and clinical implications of osteoporosis have identified novel therapeutic targets. Emerging therapies targeting novel disease mechanisms could provide powerful approaches for osteoporosis management in the future. Here, we review the etiology of osteoporosis and the molecular mechanism of bone remodeling, present current pharmacological options, and discuss emerging therapies targeting novel mechanisms, investigational treatments, and new promising therapeutic approaches.Funding Information
- National Research Foundation of Korea (2020R1A2C2012467)
This publication has 191 references indexed in Scilit:
- Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiationJournal of Cellular Biochemistry, 2011
- Advances in Glucocorticoid-Induced OsteoporosisCurrent Rheumatology Reports, 2011
- The amazing osteocyteJournal of Bone and Mineral Research, 2010
- Disruption of the Fgf2 gene activates the adipogenic and suppresses the osteogenic program in mesenchymal marrow stromal stem cellsBone, 2010
- PGC1 beta Mediates PPAR gamma Activation of Osteoclastogenesis and Rosiglitazone-Induced Bone LossCell Metabolism, 2010
- TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formationNature Medicine, 2009
- Identification of a Role for the ARHGEF3 Gene in Postmenopausal OsteoporosisAmerican Journal of Human Genetics, 2008
- An estimate of the worldwide prevalence and disability associated with osteoporotic fracturesOsteoporosis International, 2006
- Calcium plus Vitamin D Supplementation and the Risk of FracturesThe New England Journal of Medicine, 2006
- Osteoclast differentiation and activationNature, 2003